Compugen Ltd
CGEN1.460USD
-0.020-1.35%
종가 08/04, 16:00（ET）시세는 15분 지연됩니다
130.73M시가총액
손실P/E TTM
자세한 내용은 Compugen Ltd 회사
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
회사 정보
종목 코드 CGEN
회사 이름Compugen Ltd
상장일Aug 01, 2000
CEOMr. Eran Ophir
직원 수74
유형Ordinary Share
회계 연도 종료Aug 01
주소Azrieli Center
도시HOLON
증권 거래소NASDAQ Capital Market Consolidated
국가Israel
우편 번호5885849
전화97237658585
웹사이트https://cgen.com/
종목 코드 CGEN
상장일Aug 01, 2000
CEOMr. Eran Ophir
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Anat Cohen-Dayag, Ph.D.
Dr. Anat Cohen-Dayag, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
56.12K
--
Mr. Sanford (Sandy) Zweifach, CPA
Mr. Sanford (Sandy) Zweifach, CPA
Independent Director
Independent Director
--
--
Dr. Oliver Froescheis, Ph.D.
Dr. Oliver Froescheis, Ph.D.
Senior Vice President, Corporate and Business Development
Senior Vice President, Corporate and Business Development
--
--
Ms. Michelle Mahler
Ms. Michelle Mahler
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Eran Perry
Mr. Eran Perry
Independent Director
Independent Director
--
--
Dr. Kinneret Livnat Savitsky, Ph.D.
Dr. Kinneret Livnat Savitsky, Ph.D.
Independent Director
Independent Director
--
--
Mr. Gilead Halevy
Mr. Gilead Halevy
Independent Director
Independent Director
--
--
Mr. Eran Ophir
Mr. Eran Ophir
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Zurit Levine, Ph.D.
Dr. Zurit Levine, Ph.D.
Senior Vice President, Technology Innovation
Senior Vice President, Technology Innovation
--
--
Ms. Yvonne Naughton, Ph.D.
Ms. Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Head of Investor Relations and Corporate Communications
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Anat Cohen-Dayag, Ph.D.
Dr. Anat Cohen-Dayag, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
56.12K
--
Mr. Sanford (Sandy) Zweifach, CPA
Mr. Sanford (Sandy) Zweifach, CPA
Independent Director
Independent Director
--
--
Dr. Oliver Froescheis, Ph.D.
Dr. Oliver Froescheis, Ph.D.
Senior Vice President, Corporate and Business Development
Senior Vice President, Corporate and Business Development
--
--
Ms. Michelle Mahler
Ms. Michelle Mahler
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Eran Perry
Mr. Eran Perry
Independent Director
Independent Director
--
--
Dr. Kinneret Livnat Savitsky, Ph.D.
Dr. Kinneret Livnat Savitsky, Ph.D.
Independent Director
Independent Director
--
--
수익 분석
통화: USD마지막 업데이트: Sun, Jul 6
통화: USD마지막 업데이트: Sun, Jul 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
데이터 없음
지역별USD
이름
수익
비율
United States
22.86M
82.06%
Europe
5.00M
17.94%
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Wed, Jul 2
마지막 업데이트: Wed, Jul 2
주주
주주 유형
주주
주주
비율
SilverArc Capital Management, LLC
3.23%
Bristol Myers Squibb
2.06%
Renaissance Technologies LLC
1.56%
ARK Investment Management LLC
1.20%
Macquarie Investment Management
1.14%
Other
90.82%
주주
주주
비율
SilverArc Capital Management, LLC
3.23%
Bristol Myers Squibb
2.06%
Renaissance Technologies LLC
1.56%
ARK Investment Management LLC
1.20%
Macquarie Investment Management
1.14%
Other
90.82%
주주 유형
주주
비율
Hedge Fund
7.43%
Investment Advisor
6.81%
Corporation
2.06%
Investment Advisor/Hedge Fund
1.84%
Research Firm
1.05%
Individual Investor
0.06%
Family Office
0.02%
Bank and Trust
0.02%
Other
80.72%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
125
18.24M
20.37%
-2.23M
2025Q1
136
18.21M
20.34%
-1.52M
2024Q4
142
15.38M
17.17%
-4.74M
2024Q3
156
17.98M
20.08%
-1.17M
2024Q2
166
18.25M
20.39%
-8.45M
2024Q1
200
18.75M
20.95%
-8.33M
2023Q4
207
11.97M
13.42%
-16.97M
2023Q3
224
13.03M
14.74%
-15.31M
2023Q2
233
16.58M
19.07%
-11.59M
2023Q1
243
16.04M
18.70%
-15.59M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
SilverArc Capital Management, LLC
2.90M
3.23%
+1.27M
+78.25%
Mar 31, 2025
Bristol Myers Squibb
1.84M
2.06%
-2.92M
-61.32%
Dec 31, 2024
Renaissance Technologies LLC
1.40M
1.56%
+118.07K
+9.24%
Mar 31, 2025
ARK Investment Management LLC
889.67K
0.99%
+889.67K
--
Mar 31, 2025
Macquarie Investment Management
1.02M
1.14%
--
--
Mar 31, 2025
Taylor Frigon Capital Management LLC
1.05M
1.17%
-43.75K
-4.00%
Mar 31, 2025
Rock Springs Capital Management LP
989.99K
1.11%
--
--
Mar 31, 2025
Northern Trust Global Investments Limited
881.24K
0.98%
-60.59K
-6.43%
Mar 31, 2025
Morgan Stanley Smith Barney LLC
802.50K
0.9%
+23.87K
+3.07%
Mar 31, 2025
Morgan Stanley & Co. LLC
583.91K
0.65%
+543.04K
+1328.64%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
ARK Israel Innovative Technology ETF
1.64%
SPDR S&P International Small Cap ETF
0.01%
Invesco NASDAQ Future Gen 200 ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
ARK Israel Innovative Technology ETF
비율1.64%
SPDR S&P International Small Cap ETF
비율0.01%
Invesco NASDAQ Future Gen 200 ETF
비율0%
SPDR Portfolio Developed World ex-US ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
